RxDoctor Payments Data

Lee Diamond, MD

Infectious Disease · Riverdale, GANPI 1548276603

Payments from drug & device makers

$1,926in general payments, 2019–2025

Across 86 payments — averaging $22.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$431
  • AbbVie$400
  • Insmed, Inc.$364
  • Viiv Healthcare Company$169
  • Janssen Products, LP$128
  • Merck$107
  • plus $327 from 9 others

What the payments were for

  • Food & beverage$1,60683%
  • Education$32017%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,926 in reported general payments places this provider in the 50th percentile of 260 infectious disease providers in Georgia.

See all infectious disease providers in Georgia

Medicare billing

Part B allowed, 2024
$129,657
Medicare patients
187
Services billed
6,151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala270$1,112,596
GenvoyaElviteg/Cob/Emtri/Tenof Alafen274$1,105,874
TriumeqAbacavir/Dolutegravir/Lamivudi128$488,113
JulucaDolutegravir/Rilpivirine53$226,441
TivicayDolutegravir Sodium35$83,526
DescovyEmtricitabine/Tenofov Alafenam34$79,975
OdefseyEmtricitab/Rilpiviri/Tenof Ala11$44,873
PrezcobixDarunavir/Cobicistat11$31,485
Darunavir14$14,892
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam28$7,154
Ritonavir17$4,134
CeftriaxoneCeftriaxone Sodium17$1,424
ValacyclovirValacyclovir Hcl23$681
Doxycycline Monohydrate12$459
Methylphenidate Hcl12$392

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$431$2,298,445578 claims
Viiv Healthcare CompanyTriumeq, Juluca, Tivicay$169$798,080216 claims
Johnson & JohnsonPrezcobix$13$31,48511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 260 infectious disease providers in Georgia.

Other infectious disease in Riverdale

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →